uniQure N.V.
In a research report released Sunday, Oppenheimer analyst Christopher Marai maintained an Outperform rating on Uniqure NV (NASDAQ:QURE) with a price target of $47, …
Roth Capital analyst Debjit Chattopadhyay was out pounding the table on Uniqure NV (NASDAQ:QURE) Friday, reiterating a Buy rating and price target of $38 …
Piper Jaffray analyst Joshua Schimmer weighed in today with his opinions on Uniqure NV (NASDAQ:QURE) after the company released its first quarter earnings and updated …
In a research report released Friday, Chardan analyst Gbola Amusa initiated coverage on shares of Uniqure NV (NASDAQ:QURE) with a Buy rating and a $40 …
H.C.
On Monday, Uniqure NV (NASDAQ:QURE) and Bristol-Myers Squibb Co (NYSE:BMY) announced an exclusive strategic collaboration in which the agreement gives Bristol-Myers “exclusive …
Uniqure NV (NASDAQ:QURE) shares were on the rise Monday after the company announced a landmark platform deal with Bristol-Myers Squibb Co (NYSE:BMY) which will include the company's proprietary …
UniQure (NASDAQ:QURE) is delivering on the promise of gene therapy, single treatments with potentially curative results. We have developed a modular platform to …
The latest in the onslaught of biotech initial public offerings, Spark Therapeutics (ONCE) priced at $23 on Thursday evening. Twelve hours later, the stock opened at …
